Baker Brothers portfolio, Q4 2025
Baker Bros. Advisors · 13F for the quarter ending Dec 31, 2025
For Q4 2025, Baker Bros. Advisors reported $17.1B across 86 US-listed positions, led by INCY (17.8%), ONC (15.7%) and MDGL (7.3%). Compared with its filing for Q3 2025, Baker Brothers opened 9 new positions, added to 23, reduced 7 and sold out of 14; 47 positions did not change.
The largest purchase was an addition to KYMR ($156.1M); the largest sale, the sale of the whole position in Merus N V ($54.1M).
Key facts
- 13F portfolio value
- $17.1BQ4 2025
- Positions
- 86
- Largest holding
- INCY 17.8%
- New positions
- 9
- Sold out
- 14
- Filed
- Feb 17, 2026
Holdings as of (Q4 2025), filed with the SEC on . Changes are measured against the filing for Sep 30, 2025. Every tracked investor's Q4 2025 13F.
Bought and sold in Q4 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Kymera Therapeutics IncKYMR | ▲ Added 30% | +2.01M | $156.1M | 0.91% |
| Praxis Precision MedicinesPRAX | ▲ Added 63% | +437K | $128.8M | 0.75% |
| Ionis Pharmaceuticals IncIONS | ▲ Added 216% | +1.23M | $96.9M | 0.57% |
| Kodiak Sciences IncKOD | ▲ Added 15% | +2.61M | $72.9M | 0.43% |
Crinetics Pharmaceuticalsno ticker on file | ▲ Added 489% | +1.37M | $63.7M | 0.37% |
Merus N Vno ticker on file | ▼ Sold out | −574.38K | $54.1M | 0.32% |
| Alkermes PLCALKS | ▲ Added 24% | +1.92M | $53.7M | 0.31% |
| Intellia Therapeutics IncNTLA | ▼ Sold out | −2.75M | $47.4M | 0.28% |
| Summit Therapeutics IncSMMT | ▲ Added 7.9% | +2.67M | $46.7M | 0.27% |
| Stoke Therapeutics IncSTOK | ▼ Reduced 28% | −1.3M | $41.2M | 0.24% |
| Grail IncGRAL | ▲ Added 28% | +455.21K | $39M | 0.23% |
| Roivant Sciences LtdROIV | ▲ Added 47% | +1.79M | $38.8M | 0.23% |
Terns Pharmaceuticals Incno ticker on file | ▲ New | +950K | $38.4M | 0.22% |
| Arrowhead PharmaceuticalsARWR | ▲ Added 30% | +504.88K | $33.5M | 0.20% |
Avidity Biosciences Incno ticker on file | ▼ Sold out | −625K | $27.2M | 0.16% |
| Jade Biosciences IncJBIO | ▲ New | +1.64M | $25.3M | 0.15% |
| Vaxcyte IncPCVX | ▼ Sold out | −640.89K | $23.1M | 0.14% |
| BioCryst Pharmaceuticals IncBCRX | ▲ New | +2.82M | $22M | 0.13% |
Cidara Therapeutics Incno ticker on file | ▼ Sold out | −227.27K | $21.8M | 0.13% |
| Insmed IncINSM | ▼ Reduced 1.7% | −110.74K | $19.3M | 0.11% |
| Edgewise Therapeutics IncEWTX | ▼ Reduced 10.0% | −730K | $18.1M | 0.11% |
Centessa Pharmaceuticals PLCno ticker on file | ▲ New | +670.75K | $16.8M | 0.10% |
| Tectonic Therapeutic IncTECX | ▲ Added 803% | +803.4K | $16.8M | 0.10% |
| Dyne Therapeutics IncDYN | ▲ New | +813.45K | $15.9M | 0.09% |
Akero Therapeutics Incno ticker on file | ▼ Sold out | −324.63K | $15.4M | 0.09% |
| Contineum Therapeutics IncCTNM | ▲ Added more than 10× | +1.34M | $15.4M | 0.09% |
| Nurix Therapeutics IncNRIX | ▲ Added 20% | +776.43K | $14.7M | 0.09% |
Arcellx Incno ticker on file | ▼ Sold out | −166.83K | $13.7M | 0.08% |
Ventyx Biosciences Incno ticker on file | ▲ Added 130% | +1.33M | $12M | 0.07% |
| IDEAYA Biosciences IncIDYA | ▲ Added 10% | +343.38K | $11.9M | 0.07% |
| argenx SEARGX | ▼ Reduced 33% | −12.59K | $10.6M | 0.06% |
| Viking Therapeutics IncVKTX | ▼ Sold out | −366.08K | $9.6M | 0.06% |
| Monte Rosa Therapeutics IncGLUE | ▼ Reduced 12% | −570.36K | $8.9M | 0.05% |
| Structure Therapeutics IncGPCR | ▼ Reduced 7.9% | −123.58K | $8.6M | 0.05% |
| Agios Pharmaceuticals IncAGIO | ▼ Sold out | −189.87K | $7.6M | 0.04% |
| Absci CorpABSI | ▲ New | +2.13M | $7.5M | 0.04% |
| Viridian Therapeutics IncVRDN | ▲ Added 13% | +227.27K | $7.1M | 0.04% |
| Sana Biotechnology IncSANA | ▼ Reduced 85% | −1.72M | $7M | 0.04% |
| Arcus Biosciences IncRCUS | ▲ New | +270K | $6.4M | 0.04% |
| Maplight Therapeutics IncMPLT | ▲ New | +364.71K | $6.4M | 0.04% |
| Heron Therapeutics IncHRTX | ▼ Sold out | −4.25M | $5.4M | 0.03% |
| Design Therapeutics IncDSGN | ▲ Added 30% | +520.22K | $4.9M | 0.03% |
| MBX Biosciences IncMBX | ▼ Sold out | −277.78K | $4.9M | 0.03% |
| 4D Molecular TherapeuticsFDMT | ▲ New | +475.74K | $3.6M | 0.02% |
| Enliven Therapeutics IncELVN | ▲ Added 136% | +156.57K | $2.4M | 0.01% |
| Protara Therapeutics IncTARA | ▲ Added 81% | +434.78K | $2.3M | 0.01% |
| Entrada Therapeutics IncTRDA | ▲ Added 4.3% | +206.91K | $2.1M | 0.01% |
Generation Bio Cono ticker on file | ▼ Sold out | −194.49K | $1.2M | 0.01% |
| KALA BIO IncKALA | ▲ Added 83% | +818.96K | $455.3K | 0.00% |
VYNE Therapeutics Incno ticker on file | ▼ Sold out | −851.35K | $285.2K | 0.00% |
| Kiniksa Pharmaceuticals InternationalKNSA | ▲ Added 0.06% | +1.58K | $65.1K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +328 | $32.4K | 0.00% |
Opthea Limitedno ticker on file | ▼ Sold out | −2.09M | $0 | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte CorpINCY | Health Care | 17.8% | $3B | 30.74M | $98.77 | 7+ qtrs | ▲ Added 0.00% |
| 2 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 15.7% | $2.7B | 8.8M | $303.81 | 7+ qtrs | No change |
| 3 | Madrigal Pharmaceuticals IncMDGL | Health Care | 7.30% | $1.2B | 2.14M | $582.34 | 7+ qtrs | No change |
| 4 | Insmed IncINSM | Health Care | 6.72% | $1.1B | 6.59M | $174.04 | 7+ qtrs | ▼ Reduced 1.7% |
| 5 | Acadia Pharmaceuticals IncACAD | — | 6.71% | $1.1B | 42.9M | $26.71 | 7+ qtrs | No change |
| 6 | Celcuity IncCELC | — | 4.62% | $789.5M | 7.92M | $99.74 | 7+ qtrs | No change |
| 7 | Revolution Medicines IncRVMD | Health Care | 4.41% | $753.1M | 9.46M | $79.65 | 7+ qtrs | No change |
| 8 | Kymera Therapeutics IncKYMR | Health Care | 3.94% | $673.6M | 8.66M | $77.81 | 7+ qtrs | ▲ Added 30% |
| 9 | Summit Therapeutics IncSMMT | Health Care | 3.73% | $636.5M | 36.39M | $17.49 | 7+ qtrs | ▲ Added 7.9% |
| 10 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.51% | $599.9M | 5.6M | $107.04 | 7+ qtrs | No change |
| 11 | Kodiak Sciences IncKOD | Health Care | 3.26% | $556.9M | 19.92M | $27.96 | 7+ qtrs | ▲ Added 15% |
| 12 | Praxis Precision MedicinesPRAX | Health Care | 1.94% | $332M | 1.13M | $294.74 | 7+ qtrs | ▲ Added 63% |
| 13 | Alkermes PLCALKS · SHS | Health Care | 1.64% | $280.1M | 10.01M | $27.98 | 7+ qtrs | ▲ Added 24% |
| 14 | Grail IncGRAL | Health Care | 1.05% | $178.5M | 2.09M | $85.59 | 5 qtrs | ▲ Added 28% |
| 15 | Edgewise Therapeutics IncEWTX | Health Care | 0.96% | $163.2M | 6.58M | $24.81 | 7+ qtrs | ▼ Reduced 10.0% |
| 16 | Arrowhead PharmaceuticalsARWR | Health Care | 0.85% | $144.4M | 2.18M | $66.39 | 3 qtrs | ▲ Added 30% |
| 17 | Ionis Pharmaceuticals IncIONS | Health Care | 0.83% | $141.8M | 1.79M | $79.11 | 2 qtrs | ▲ Added 216% |
| 18 | Immunovant IncIMVT | Health Care | 0.81% | $138.7M | 5.46M | $25.42 | 7+ qtrs | No change |
| 19 | Immatics N.V.IMTX · SHS | — | 0.74% | $127M | 12.09M | $10.50 | 7+ qtrs | No change |
| 20 | IDEAYA Biosciences IncIDYA | — | 0.73% | $125.1M | 3.62M | $34.57 | 7+ qtrs | ▲ Added 10% |
| 21 | Roivant Sciences LtdROIV · SHS | Health Care | 0.71% | $120.5M | 5.56M | $21.70 | 7+ qtrs | ▲ Added 47% |
| 22 | Abivax SAABVX · SPONSORED ADS | Health Care | 0.69% | $118.1M | 875.8K | $134.86 | 2 qtrs | No change |
| 23 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.68% | $116.6M | 2.83M | $41.25 | 7+ qtrs | ▲ Added 0.06% |
| 24 | Replimune Group IncREPL | — | 0.63% | $107.4M | 11.05M | $9.72 | 7+ qtrs | No change |
| 25 | Stoke Therapeutics IncSTOK | — | 0.62% | $105.9M | 3.34M | $31.74 | 7+ qtrs | ▼ Reduced 28% |
| 26 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.58% | $99.6M | 1.43M | $69.55 | 6 qtrs | ▼ Reduced 7.9% |
| 27 | Abcellera Biologics IncABCL | — | 0.55% | $94.1M | 27.53M | $3.42 | 7+ qtrs | No change |
| 28 | Nurix Therapeutics IncNRIX | — | 0.52% | $88.4M | 4.66M | $18.97 | 7+ qtrs | ▲ Added 20% |
| 29 | Immunocore Holdings plcIMCR · ADS | — | 0.47% | $80.6M | 2.32M | $34.71 | 7+ qtrs | No change |
| 30 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 0.45% | $77.1M | 10.89M | $7.08 | 7+ qtrs | No change |
| 31 | Crinetics Pharmaceuticalsno ticker on file | — | 0.45% | $76.8M | 1.65M | $46.55 | 3 qtrs | ▲ Added 489% |
| 32 | Monte Rosa Therapeutics IncGLUE | — | 0.40% | $68.1M | 4.35M | $15.68 | 7+ qtrs | ▼ Reduced 12% |
| 33 | Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031 | — | 0.39% | $66.6M | — | — | 2 qtrs | No change |
| 34 | Ultragenyx PharmaceuticalRARE | — | 0.37% | $63.8M | 2.77M | $23.00 | 7+ qtrs | No change |
| 35 | Denali Therapeutics IncDNLI | — | 0.36% | $61.6M | 3.73M | $16.51 | 7+ qtrs | No change |
| 36 | Viridian Therapeutics IncVRDN | — | 0.36% | $61.4M | 1.97M | $31.12 | 3 qtrs | ▲ Added 13% |
| 37 | Entrada Therapeutics IncTRDA | — | 0.31% | $52.1M | 5.07M | $10.28 | 7+ qtrs | ▲ Added 4.3% |
| 38 | Rapport Therapeutics IncRAPP | — | 0.28% | $46.9M | 1.55M | $30.34 | 3 qtrs | No change |
| 39 | Terns Pharmaceuticals Incno ticker on file | — | 0.23% | $38.4M | 950K | $40.40 | 1 qtr | New |
| 40 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.21% | $35.1M | 368.92K | $95.20 | 5 qtrs | No change |
| 41 | Spyre Therapeutics IncSYRE | Health Care | 0.19% | $32.8M | 1M | $32.76 | 3 qtrs | No change |
| 42 | Dianthus Therapeutics IncDNTH | Health Care | 0.19% | $32.5M | 789.76K | $41.21 | 3 qtrs | No change |
| 43 | Prelude Therapeutics IncPRLD | — | 0.17% | $29.4M | 10.12M | $2.90 | 7+ qtrs | No change |
| 44 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.16% | $28M | 1.46M | $19.17 | 7+ qtrs | No change |
| 45 | Disc Medicine IncIRON | — | 0.16% | $26.8M | 337.05K | $79.41 | 5 qtrs | No change |
| 46 | Jade Biosciences IncJBIO | — | 0.15% | $25.3M | 1.64M | $15.43 | 1 qtr | New |
| 47 | Taysha Gene Therapies IncTSHA | — | 0.13% | $22M | 4M | $5.50 | 7+ qtrs | No change |
| 48 | BioCryst Pharmaceuticals IncBCRX | — | 0.13% | $22M | 2.82M | $7.80 | 1 qtr | New |
| 49 | Ventyx Biosciences Incno ticker on file | — | 0.12% | $21.2M | 2.35M | $9.03 | 2 qtrs | ▲ Added 130% |
| 50 | argenx SEARGX · SPONSORED ADR | Health Care | 0.12% | $21.2M | 25.17K | $840.95 | 7+ qtrs | ▼ Reduced 33% |
| 51 | Design Therapeutics IncDSGN | — | 0.12% | $20.9M | 2.23M | $9.38 | 7+ qtrs | ▲ Added 30% |
| 52 | Cerus CorpCERS | — | 0.12% | $20.6M | 10.01M | $2.06 | 7+ qtrs | No change |
| 53 | Neurogene IncNGNE | — | 0.12% | $20.4M | 991.69K | $20.60 | 7+ qtrs | No change |
| 54 | Tectonic Therapeutic IncTECX | — | 0.11% | $18.8M | 903.4K | $20.86 | 4 qtrs | ▲ Added 803% |
| 55 | CytomX Therapeutics IncCTMX | — | 0.11% | $18.1M | 4.25M | $4.26 | 3 qtrs | No change |
| 56 | Celldex Therapeutics IncCLDX | — | 0.11% | $18.1M | 665.37K | $27.16 | 7+ qtrs | No change |
| 57 | Xencor IncXNCR | — | 0.10% | $16.9M | 1.1M | $15.31 | 7+ qtrs | No change |
| 58 | Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS | — | 0.10% | $16.8M | 670.75K | $25.01 | 1 qtr | New |
| 59 | Xenon Pharmaceuticals IncXENE | — | 0.10% | $16.6M | 370.21K | $44.82 | 7+ qtrs | No change |
| 60 | Sionna Therapeutics IncSION | — | 0.10% | $16.5M | 400K | $41.14 | 4 qtrs | No change |
| 61 | Contineum Therapeutics IncCTNM · CL A | — | 0.10% | $16.2M | 1.42M | $11.43 | 7+ qtrs | ▲ Added more than 10× |
| 62 | Sera Prognostics IncSERA · CLASS A COM | — | 0.10% | $16.2M | 5.5M | $2.95 | 7+ qtrs | No change |
| 63 | Dyne Therapeutics IncDYN | — | 0.09% | $15.9M | 813.45K | $19.56 | 1 qtr | New |
| 64 | Alumis IncALMS | — | 0.09% | $15.3M | 1.56M | $9.76 | 7+ qtrs | No change |
| 65 | Nuvalent Incno ticker on file | — | 0.09% | $14.5M | 143.94K | $100.59 | 3 qtrs | No change |
| 66 | Pharvaris N VPHVS | — | 0.06% | $10.4M | 375K | $27.75 | 2 qtrs | No change |
| 67 | Relay Therapeutics IncRLAY | — | 0.06% | $9.8M | 1.16M | $8.46 | 7+ qtrs | No change |
| 68 | Absci CorpABSI | — | 0.04% | $7.5M | 2.13M | $3.49 | 1 qtr | New |
| 69 | Arcus Biosciences IncRCUS | — | 0.04% | $6.4M | 270K | $23.83 | 1 qtr | New |
| 70 | Maplight Therapeutics IncMPLT | — | 0.04% | $6.4M | 364.71K | $17.56 | 1 qtr | New |
| 71 | vTv Therapeutics IncVTVT · CL A | — | 0.04% | $5.9M | 148.31K | $39.99 | 7+ qtrs | No change |
| 72 | Wave Life Sciences LtdWVE · SHS | — | 0.03% | $5.8M | 344.06K | $17.00 | 6 qtrs | No change |
| 73 | Sagimet Biosciences IncSGMT | — | 0.03% | $5.6M | 953K | $5.92 | 7+ qtrs | No change |
| 74 | Protara Therapeutics IncTARA | — | 0.03% | $5.2M | 971.61K | $5.33 | 7+ qtrs | ▲ Added 81% |
| 75 | LB Pharmaceuticals IncLBRX | — | 0.03% | $4.5M | 200K | $22.26 | 2 qtrs | No change |
| 76 | Enliven Therapeutics IncELVN | — | 0.02% | $4.2M | 271.41K | $15.40 | 7+ qtrs | ▲ Added 136% |
| 77 | 4D Molecular TherapeuticsFDMT | — | 0.02% | $3.6M | 475.74K | $7.50 | 1 qtr | New |
| 78 | Vir Biotechnology IncVIR | — | 0.02% | $3.3M | 542.54K | $6.03 | 5 qtrs | No change |
| 79 | TScan Therapeutics IncTCRX | — | 0.02% | $2.8M | 2.78M | $1.00 | 7+ qtrs | No change |
| 80 | Sana Biotechnology IncSANA | — | 0.01% | $1.3M | 310.48K | $4.07 | 7+ qtrs | ▼ Reduced 85% |
| 81 | Skye Bioscience IncSKYE | — | 0.01% | $1.1M | 1.45M | $0.7497 | 7+ qtrs | No change |
| 82 | KALA BIO IncKALA | — | 0.01% | $1M | 1.8M | $0.5559 | 7+ qtrs | ▲ Added 83% |
| 83 | Aligos Therapeutics IncALGS | — | 0.01% | $774.1K | 83.06K | $9.32 | 7+ qtrs | No change |
| 84 | Tyra Biosciences IncTYRA | — | 0.00% | $278.9K | 10.61K | $26.29 | 7+ qtrs | No change |
| 85 | Acrivon Therapeutics IncACRV | — | 0.00% | $55K | 22.81K | $2.41 | 7+ qtrs | No change |
| 86 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $16.7K | 833.33K | $0.0200 | 7+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 77.2% | $13.2B | 23 |
| No sector on file | 22.8% | $3.9B | 63 |
Questions and answers
What did Baker Brothers own in Q4 2025?
Baker Bros. Advisors's 13F for Q4 2025 lists 86 positions worth $17.1B. The largest: INCY (17.8%), ONC (15.7%), MDGL (7.3%), INSM (6.7%), ACAD (6.7%).
What did Baker Brothers buy in Q4 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: KYMR (added, $156.1M), PRAX (added, $128.8M), IONS (added, $96.9M), KOD (added, $72.9M), Crinetics Pharmaceuticals (added, $63.7M), ALKS (added, $53.7M).
What did Baker Brothers sell in Q4 2025?
The largest sales: Merus N V (sold out, $54.1M), NTLA (sold out, $47.4M), STOK (reduced, $41.2M), Avidity Biosciences Inc (sold out, $27.2M), PCVX (sold out, $23.1M), Cidara Therapeutics Inc (sold out, $21.8M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Dec 31, 2025 on Feb 17, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q4 2025: Baker Bros. Advisors 13F holdings”, data as of 17 February 2026. https://funkfolio.com/gurus/baker-brothers/2025-q4
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Dec 31, 2025.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Dec 31, 2025, filed Feb 17, 2026. Changes compare share counts with the filing for Sep 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $17.1B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 7 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.